SENTRY Antimicrobial Surveillance Program

SENTRY Antimicrobial Surveillance Program
Name	SENTRY Antimicrobial Surveillance Program
Established	1997
Type	Surveillance network
Headquarters	North America
Region served	Global
Parent organization	JMI Laboratories

SENTRY Antimicrobial Surveillance Program

The SENTRY Antimicrobial Surveillance Program is a global surveillance initiative that monitors patterns of antimicrobial resistance and pathogen prevalence across clinical settings. Founded in the late 20th century, the program collects and analyzes isolates from hospitals and laboratories to inform antimicrobial stewardship, drug development, and public health policy. Its datasets have been cited alongside work from organizations such as Centers for Disease Control and Prevention, World Health Organization, European Centre for Disease Prevention and Control, Food and Drug Administration, and World Bank in studies of bacterial and fungal resistance trends.

Overview

SENTRY operates as a networked laboratory surveillance program similar in scope to National Healthcare Safety Network, Active Bacterial Core surveillance, and European Antimicrobial Resistance Surveillance Network, aggregating clinical isolates from diverse regions including North America, Europe, Asia, Latin America, Africa, and the Western Pacific. The program partners with academic institutions such as Johns Hopkins University, Harvard Medical School, and University of Oxford as well as private organizations like JMI Laboratories and pharmaceutical companies including Pfizer, Merck & Co., and GlaxoSmithKline. Data outputs are used by regulatory bodies such as European Medicines Agency and Medicines and Healthcare products Regulatory Agency to support antimicrobial susceptibility breakpoints and clinical trial design.

History and Development

The program was initiated in the 1990s amid rising attention to resistant pathogens following landmark reports from entities like Institute of Medicine and events such as the spread of methicillin-resistant Staphylococcus aureus and outbreaks linked to Pseudomonas aeruginosa. Early collaborators included investigators connected to Centers for Disease Control and Prevention, Walter Reed Army Institute of Research, and university laboratories at University of Iowa and University of Toronto. Over time SENTRY expanded methodology influenced by surveillance precedents like the International Nosocomial Infection Control Consortium and surveillance studies reported in journals associated with American Society for Microbiology, The Lancet, and New England Journal of Medicine.

Methodology

SENTRY uses standardized isolate collection protocols influenced by laboratory standards from Clinical and Laboratory Standards Institute and testing methods recognized by European Committee on Antimicrobial Susceptibility Testing. Participating sites submit clinical isolates from specimen sources such as bloodstream, respiratory tract, skin and soft tissue, and urinary tract, which are identified using technologies like matrix-assisted laser desorption ionization–time of flight mass spectrometry and molecular assays comparable to those developed at Centers for Disease Control and Prevention laboratories. Antimicrobial susceptibility testing employs broth microdilution, Etest, and genetic resistance determinant screening analogous to methods used by Broad Institute and Wellcome Trust Sanger Institute for genomic surveillance. Data are curated, quality-controlled, and analyzed with biostatistical approaches paralleling those at Johns Hopkins Bloomberg School of Public Health and visualized in formats used by World Health Organization reports.

Key Findings and Impact

SENTRY has documented trends in resistance among key pathogens including Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Enterococcus faecalis, and fungi such as Candida albicans and Candida auris. Findings have informed clinical guidelines from organizations like Infectious Diseases Society of America and influenced antimicrobial stewardship initiatives at hospitals affiliated with Mayo Clinic, Cleveland Clinic, and Massachusetts General Hospital. The program's data supported drug development programs at companies such as AstraZeneca and Novartis and were referenced in regulatory submissions to Food and Drug Administration and European Medicines Agency. SENTRY reports have been cited in global assessments by World Health Organization and incorporated into modeling studies by institutions such as Imperial College London and University College London.

Participating Sites and Governance

SENTRY's network comprises clinical laboratories, tertiary care hospitals, and reference centers across continents, with contributors from institutions like Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, National University Hospital (Singapore), Auckland City Hospital, and university medical centers in Germany, France, Spain, Italy, and Japan. Governance involves collaboration between private laboratory organizations, academic partners, and advisory boards that include representatives with affiliations to Royal College of Physicians, Society for Healthcare Epidemiology of America, and regulatory agencies such as Health Canada. Data sharing agreements and ethics oversight are structured to align with policies espoused by institutions like National Institutes of Health and international ethical frameworks developed post-Declaration of Helsinki.

Limitations and Criticisms

Critics have noted potential biases related to sentinel site selection similar to critiques faced by Global Antimicrobial Resistance Surveillance System and challenges in representativeness across low- and middle-income regions compared with high-income settings like United States and United Kingdom. Methodological limitations include variability in isolate submission practices, comparability concerns with routine clinical laboratory data used by Public Health England and reliance on centralized testing that may not capture local outbreak dynamics documented in reports from Médecins Sans Frontières and Centers for Disease Control and Prevention. Transparency advocates have called for increased public access to raw datasets analogous to open data initiatives at European Centre for Disease Prevention and Control while funders and stakeholders debate sustainability similar to conversations involving Gates Foundation and international donors.

Category:Antimicrobial resistance Category:Infectious disease surveillance programs